GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » DexCom Inc (NAS:DXCM) » Definitions » Total Assets

DXCM (DexCom) Total Assets : $6,752 Mil (As of Mar. 2025)


View and export this data going back to 2005. Start your Free Trial

What is DexCom Total Assets?

DexCom's Total Assets for the quarter that ended in Mar. 2025 was $6,752 Mil.

Warning Sign:

If a company builds assets at 34.1% a year, faster than its revenue growth rate of 19.6% over the past 5 years, it means that the company may be getting less efficient.

During the past 12 months, DexCom's average Total Assets Growth Rate was 13.00% per year. During the past 3 years, the average Total Assets Growth Rate was 21.00% per year. During the past 5 years, the average Total Assets Growth Rate was 34.10% per year. During the past 10 years, the average Total Assets Growth Rate was 46.60% per year.

During the past 13 years, DexCom's highest 3-Year average Total Assets Growth Rate was 137.40%. The lowest was 17.30%. And the median was 44.20%.

Total Assets is connected with ROA %. DexCom's annualized ROA % for the quarter that ended in Mar. 2025 was 6.37%. Total Assets is also linked to Revenue through Asset Turnover. DexCom's Asset Turnover for the quarter that ended in Mar. 2025 was 0.16.


DexCom Total Assets Historical Data

The historical data trend for DexCom's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DexCom Total Assets Chart

DexCom Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4,290.50 4,933.30 5,391.70 6,264.50 6,484.50

DexCom Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6,482.20 6,799.20 6,353.80 6,484.50 6,751.70

DexCom Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

DexCom's Total Assets for the fiscal year that ended in Dec. 2024 is calculated as

Total Assets=Total Equity (A: Dec. 2024 )+Total Liabilities (A: Dec. 2024 )
=2102.6+4381.9
=6,485

DexCom's Total Assets for the quarter that ended in Mar. 2025 is calculated as

Total Assets=Total Equity (Q: Mar. 2025 )+Total Liabilities (Q: Mar. 2025 )
=2266.6+4485.1
=6,752

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


DexCom  (NAS:DXCM) Total Assets Explanation

Total Assets is connected with ROA %.

DexCom's annualized ROA % for the quarter that ended in Mar. 2025 is

ROA %=Net Income (Q: Mar. 2025 )/( (Total Assets (Q: Dec. 2024 )+Total Assets (Q: Mar. 2025 ))/ count )
=421.6/( (6484.5+6751.7)/ 2 )
=421.6/6618.1
=6.37 %

Note: The Net Income data used here is four times the quarterly (Mar. 2025) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

DexCom's Asset Turnover for the quarter that ended in Mar. 2025 is

Asset Turnover
=Revenue (Q: Mar. 2025 )/( (Total Assets (Q: Dec. 2024 )+Total Assets (Q: Mar. 2025 ))/ count )
=1036/( (6484.5+6751.7)/ 2 )
=1036/6618.1
=0.16

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

DexCom Total Assets Related Terms

Thank you for viewing the detailed overview of DexCom's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


DexCom Business Description

Address
6340 Sequence Drive, San Diego, CA, USA, 92121
Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
Executives
Sadie Stern officer: Chief Human Resources Officer 6340 SEQUENCE DRIVE, SAN DIEGO CA 92121
Micheal Jon Brown officer: EVP, Chief Legal Officer 6340 SEQUENCE DR, SAN DIEGO CA 92121
Bridgette P Heller director TECH DATA CORPORATION, 5350 TECH DATA DRIVE, CLEARWATER FL 33760
Jacob Steven Leach officer: SVP, Research & Development 6340 SEQUENCE DRIVE, SAN DIEGO CA 92121
Jereme M Sylvain officer: SVP, Finance & CAO 6340 SEQUENCE DRIVE, SAN DIEGO X1 92121
Kevin R Sayer director
Matthew Vincent Dolan officer: * 6340 SEQUENCE DR, SAN DIEGO CA 92121
Mark G Foletta director AMYLIN PHARMACEUTICALS INC, 9360 TOWNE CENTRE DR, SAN DIEGO CA 92121
Teri L Lawver officer: EVP Chief Commercial Officer C/O DEXCOM, INC., 6340 SEQUENCE DRIVE, SAN DIEGO CA 92121
Steven R Altman director
Nicholas Augustinos director 754 GRAND VIEW AVENUE, SAN FRANCISCO CA 94114
Steven Robert Pacelli officer: Vice President Legal Affairs 5555 OBERLIN DRIVE, SAN DIEGO CA 92121
Girish Naganathan officer: EVP Chief Technology Officer C/O DEXCOM, INC., 6340 SEQUENCE DRIVE, SAN DIEGO CA 92121
Barry J. Regan officer: EVP Operations 1023 CHERRY ROAD, MEMPHIS TN 38117
Rimma Driscoll director C/O ZOETIS INC., 10 SYLVAN WAY, PARSIPPANY NJ 07054